A Study of LY3023414 and Necitumumab in Squamous Lung Cancer: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of LY3023414 and Necitumumab in Squamous Lung Cancer (NCT02443337), a na phase 2 study. The primary outcome is Percentage of Participants With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at 6 Months: Disease Control Rate (DCR).

2. Clinical Question

3. Trial Design

This phase II study evaluated LY3023414 in combination with necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer. The registry lists an enrollment of 31 and identifies the design as single-group, with no masking. Allocation is recorded as not applicable. The study status is terminated; the reason for termination is not reported in the registry record.

The treatment description specifies LY3023414 at 200 milligrams by mouth twice daily, together with 800 mg of necitumumab by intravenous administration on day 1 and day 8 of each 21 day cycle. Participants could continue treatment until discontinuation criteria were met. The record does not report further details about those criteria.

The adverse-event record distinguishes a lead-in cohort and a post lead-in cohort. Both are described as receiving LY3023414 plus necitumumab. The lead-in labels do not establish a randomized comparison, and differences between these cohorts cannot be interpreted as treatment effects against a control. The registry explicitly cautions that the arms are not a like-for-like control comparison.

The study began in 2015-07, and primary completion is recorded as 2017-09. The brief summary says the main purpose was to evaluate safety and activity of the combination. The primary outcome was disease control at six months. Secondary outcomes included objective response rate, progression-free survival, overall survival, and pharmacokinetic measures for both drugs. The registry lists six outcome measures, but does not report numerical results for the primary or secondary outcomes. Further design details, including the statistical plan and the reason for the chosen enrollment, are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants completed the study if they had objective progressive disease (PD), stable disease (SD), complete response (CR) or partial response (PR).

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All participants who received at least one dose of study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All participants who received at least one dose of study drug.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at 6 Months: Disease Control Rate (DCR), measured over 6 Months.

The primary endpoint is titled as the percentage of participants with complete response, partial response, or stable disease at six months, termed the disease control rate. Its description operationalizes the measure as participants with progression-free survival beyond six months divided by participants with baseline tumor assessment. The record notes that the six-month threshold could be treated as 26 weeks to accommodate a tumor assessment at week 24 delayed by up to two weeks. The endpoint title and its operational definition therefore use related but not identical descriptions: one names response categories, while the stated calculation uses progression-free survival.

Response was assessed using RECIST v 1.1. The record defines complete response and partial response for target lesions by changes in lesion visibility or the sum of diameters, and also describes complete response and stable disease for non-target lesions. These criteria provide a structured way to classify tumor status. A disease-control measure combines tumor shrinkage or stability with a time requirement, so it represents a different outcome from objective response alone.

Such an endpoint can describe whether disease remained controlled through a specified follow-up point, but its interpretation depends on how the assessment window, denominator, and missing evaluations are handled. Those handling details and the observed disease-control percentage are not reported in the registry record. The registry also does not report the 95% confidence interval attached to the primary endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does the confidence interval describe?

The primary endpoint specifies a 95% confidence interval around a percentage. In general, a confidence interval expresses the uncertainty associated with an estimate under the statistical method used. A narrower interval indicates greater precision under that method, while a wider interval indicates less precision. The registry record does not report the interval limits, the endpoint percentage, or the method used to calculate the interval. Its precision therefore cannot be evaluated from the posted results.

How is disease control defined?

The endpoint description states that disease control at six months is calculated from participants with progression-free survival beyond six months, using participants with baseline tumor assessment as the denominator. It also allows the six-month point to be expressed as 26 weeks to accommodate a scheduled tumor assessment at week 24 delayed by up to two weeks. This timing rule is part of the endpoint definition, not evidence that every participant had an assessment in that window.

The endpoint title names complete response, partial response, and stable disease, while the stated calculation uses progression-free survival beyond the time threshold. Readers should keep both descriptions in view. The registry does not provide further detail that reconciles them, nor does it give an observed numerator or denominator. General statistical interpretation of any percentage depends on both the event definition and the population included in its denominator.

How do the response criteria work?

The record says tumor response was assessed using RECIST v 1.1. For target lesions, complete response means disappearance of all target lesions. Partial response is defined as at least a 30% decrease in the sum of target-lesion diameters, relative to baseline. Stable disease means neither enough shrinkage to qualify as partial response nor enough increase to qualify as progressive disease, relative to the smallest sum of diameters since treatment began.

For non-target lesions, complete response is defined as disappearance of all non-target lesions and normalization of tumor markers. The record states that lymph nodes must be non-pathological in size, with a short axis <10 millimeters. Stable disease is described as persistence of one or more non-target lesions and/or tumor markers remaining above normal limits. These definitions explain the classification rules, but do not reveal which classifications occurred in the study.

Why does a single-group design affect inference?

In general, a single-group study can describe outcomes observed among participants receiving a regimen, but it lacks a concurrent randomized comparison to separate treatment-associated outcomes from other influences. The record identifies lead-in and post lead-in cohorts, but both are receiving the combination. It explicitly warns that the cohorts are not a like-for-like control comparison. Differences between their recorded outcomes, if reported, would not automatically provide a causal estimate of treatment benefit.

Randomization and masking are recorded as not applicable and none, respectively. The registry does not report the rationale for the design, a statistical analysis plan, or any planned adjustment strategy. Those details should not be inferred from the phase or the listed outcomes.

What do the safety counts represent?

The safety record reports, for each cohort, the number at risk and the number affected for serious events and other events, along with deaths. These are descriptive counts. General comparison of counts requires attention to the population at risk, follow-up duration, and event definitions. The record does not provide enough detail to infer rates over time, causal attribution, or whether events were treatment-related. The listed serious-event terms also include percentages, but the registry does not state additional context for interpreting those percentages.

What can be inferred from the listed analyses?

The registry lists no analyses. In general, an analysis estimate, its uncertainty, and the method used to obtain it are needed to evaluate an endpoint quantitatively. No primary endpoint result, confidence interval limits, or outcome-specific model is reported in the registry record. A statistical plan, including any interim analyses, is also not reported. Without those details, it is not possible to assess the analysis choices or determine whether the reported endpoint was analyzed as planned.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Lead in Cohort LY3023414 + Necitumumab", "Post Lead in Cohort LY3023414 + Necitumumab")
n      <- c(15, 16)
events <- c(1, 4)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Lead in Cohort LY3023414 + Necitumumab  15  1  6.7  0.2  31.9  1.2  29.8  1.6  30.2
ARM  Post Lead in Cohort LY3023414 + Necitumumab  16  4  25.0  7.3  52.4  10.2  49.5  10.3  49.9

11. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary endpoint and several secondary outcomes: objective response rate, progression-free survival, overall survival, and pharmacokinetic minimum and maximum concentrations for LY3023414 and necitumumab. It does not report numerical results for these outcomes or describe a strategy for handling multiple statistical tests. In general, testing several outcomes can increase the chance of finding an apparently notable result by chance; multiplicity procedures are one way to address that issue. Whether any such procedure was planned or used is not reported in the registry record.

The record lists no analyses. It does not describe interim analyses, a statistical analysis plan, or whether any outcomes were adjusted for covariates. These details should not be inferred from the phase or endpoint list.

The primary population is described as all participants who received at least one dose of study drug. The endpoint denominator is described separately as participants with baseline tumor assessment. The record does not report the number included in either population, how missing baseline or follow-up assessments were handled, or whether participants who discontinued treatment remained in the endpoint analysis. It also does not state how the delayed assessment allowance was applied to individual participants.

In general, missing outcome data can affect a percentage when participants without an assessment are excluded or classified in a particular way. The effect depends on why data are missing and the analysis rule. Those rules are not reported in the registry record, so the direction or extent of any potential missing-data impact cannot be assessed.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: atrial fibrillation (6.7%), atrial flutter (6.7%), constipation (6.7%), haematoma (6.7%), diarrhoea (6.2%).

The registry gives separate safety figures for the lead-in cohort and post lead-in cohort. For the lead-in cohort, 15 participants are listed at risk for serious events and 3 as affected; 15 are listed at risk for other events and 15 as affected, with 11 deaths recorded. For the post lead-in cohort, 16 are listed at risk for serious events and 5 as affected; 16 are listed at risk for other events and 16 as affected, with 6 deaths recorded. These are descriptive registry counts, not a randomized comparison.

The serious-event terms listed include atrial fibrillation, atrial flutter, constipation, and haematoma, each at 6.7%, and diarrhoea and vomiting, each at 6.2%. The record does not provide further details about the event definitions, timing, duration, attribution, or the basis for the percentages. It also does not establish whether a participant could contribute to more than one term. The counts and percentages should therefore be read as the registry’s recorded safety information, not as estimates of comparative risk or proof that an event was caused by treatment.

The lead-in and post lead-in cohorts both received the combination and are not a like-for-like control comparison. The record does not explain the deaths or state their relationship to treatment. Safety interpretation beyond these descriptive entries is not supported by the registry record.

13. What the Result Does, and Does Not, Mean

The registry describes a phase II study of LY3023414 plus necitumumab in metastatic squamous non-small cell lung cancer after first-line chemotherapy. It identifies disease control at six months as the primary outcome and gives response assessment definitions. It also records safety counts for two cohorts receiving the combination.

Those details do not establish the observed primary outcome. The registry record does not report the disease-control percentage, its 95% confidence interval, or the endpoint denominator. It also does not provide numerical results for the listed secondary outcomes. Without those results, the frequency of disease control and the precision of any estimate cannot be judged from the posted information.

The endpoint title and its operational definition are not fully aligned: the title refers to response categories, while the calculation is stated in terms of progression-free survival beyond six months. This distinction should be considered when interpreting any result reported elsewhere, but the registry does not provide further clarification.

The single-group design has no concurrent randomized control arm. The two safety cohorts are both described as receiving the combination, so they do not establish a comparative treatment effect. General inference from a single-group study is limited because observed outcomes cannot be directly contrasted with outcomes under another treatment within the same randomized trial.

The safety entries are descriptive and do not include enough information to establish causality, event timing, or comparative risk. The record’s terminated status is noted, but its reason is not reported. Overall, the registry supports a description of the study question and design, but not a numerical conclusion about efficacy or a causal conclusion about benefit or harm.

14. Why This Trial Matters Statistically

This trial raises several statistical interpretation issues that are important in clinical research. Its primary outcome combines a time threshold with response-related language. The title describes complete response, partial response, or stable disease at six months, while the endpoint definition uses progression-free survival beyond six months. A clear distinction between endpoint label, event definition, time point, and denominator is essential when interpreting a clinical result.

The study also illustrates the limits of an uncontrolled design. A single-group study can record outcomes after treatment, but without a concurrent randomized comparator it cannot isolate the contribution of the regimen from other influences. The lead-in and post lead-in cohorts do not serve as like-for-like controls because both receive the combination.

Precision matters as much as the point estimate. The primary endpoint specifies a 95% confidence interval, but neither the interval nor the estimated percentage is reported in the registry record. Without both, readers cannot assess how uncertain the endpoint estimate would be. The absence of outcome analyses also means that the listed secondary outcomes cannot be used to build a fuller quantitative picture.

Finally, the distinction between enrollment and the analysis population matters. The registry gives an enrollment figure, while the primary population and denominator are defined using treatment exposure and baseline tumor assessment. Missing-data handling and the relationship between these populations are not described. Clear reporting of these features is necessary for readers to understand what a percentage represents and how broadly it applies.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations affect interpretation of the registry record. First, the study is single-group and has no randomized comparator. The lead-in and post lead-in cohorts both received LY3023414 plus necitumumab, and the record cautions that the arms are not a like-for-like control comparison. The cohort labels therefore do not support a controlled estimate of treatment effect.

Second, the primary outcome result is not reported. The record provides no disease-control percentage, confidence interval limits, or endpoint denominator. The listed secondary outcomes also lack numerical results. This prevents an assessment of the magnitude and precision of the reported clinical outcomes.

Third, the primary endpoint title and its operational definition differ in emphasis. The title names response categories at six months; the definition counts progression-free survival beyond six months among participants with baseline tumor assessment. The registry does not explain this relationship further.

Fourth, the endpoint population is described as participants receiving at least one dose, while its denominator refers to baseline tumor assessment. The record does not state how many participants met either definition, how missing assessments were handled, or how discontinuations affected analysis.

Finally, the study is listed as terminated, but the reason is not reported. The registry does not report a statistical analysis plan, interim analysis details, multiplicity handling, or methods for the confidence interval. The safety counts lack context on timing, attribution, and event definitions. These limitations are specific to the information recorded and do not establish why the study ended or what its unreported analyses would have shown.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Study of LY3023414 and Necitumumab in Squamous Lung Cancer — NCT02443337.
• Registry record last updated 2020-12-09; status last verified 2018-01.
• Results first posted 2020-12-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT02443337 is a phase II, single-group study of LY3023414 plus necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer. The study is listed as terminated, with enrollment of 31. The primary endpoint is disease control at six months, with a specified 95% confidence interval, but the endpoint result and interval are not reported in the registry record.

The registry describes RECIST v 1.1 response criteria, lists objective response rate, progression-free survival, overall survival, and pharmacokinetic outcomes, and records safety counts for lead-in and post lead-in cohorts. Both cohorts received the combination; they are not a randomized control comparison. The reason for termination, analysis methods, missing-data handling, and numerical results for the primary and secondary outcomes are not reported.